Patents by Inventor Simon METENOU

Simon METENOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION CONSTRUCTS AND METHODS OF USING THEREOF
    Publication number: 20240141045
    Abstract: Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-? trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
    Type: Application
    Filed: November 23, 2022
    Publication date: May 2, 2024
    Applicant: PRECIGEN, INC.
    Inventors: Helen SABZEVARI, Simon METENOU, ChangHung CHEN, Rutul R. SHAH
  • HEPATITIS B VACCINES AND USES OF THE SAME
    Publication number: 20230279057
    Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Application
    Filed: December 2, 2022
    Publication date: September 7, 2023
    Applicant: Precigen, Inc.
    Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Prabakaran PONRAJ, Simon METENOU, Kuan-Fu DING
  • Hepatitis B vaccines and uses of the same
    Patent number: 11608362
    Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 21, 2023
    Assignee: Precigen, Inc.
    Inventors: Douglas E. Brough, Cheryl G. Bolinger, Ramya Yarlagadda, Vinodhbabu Kurella, Prabakaran Ponraj, Simon Metenou, Kuan-Fu Ding
  • Fusion constructs and methods of using thereof
    Patent number: 11535669
    Abstract: Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-? trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: December 27, 2022
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Simon Metenou, ChangHung Chen, Rutul R. Shah
  • FUSION CONSTRUCTS AND METHODS OF USING THEREOF
    Publication number: 20220023420
    Abstract: A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-? trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 27, 2022
    Applicant: Precigen, Inc.
    Inventors: Helen SABZEVARI, Simon METENOU, Chang Hung CHEN, Rutul SHAH
  • HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
    Publication number: 20210024586
    Abstract: Provided herein are engineered human papilloma virus (HPV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 28, 2021
    Applicants: Precigen, Inc., PGEN Therapeutics, Inc.
    Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Ponraj PRABAKARAN, Simon METENOU, Kuan-Fu DING
  • HEPATITIS B VACCINES AND USES OF THE SAME
    Publication number: 20210015911
    Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 21, 2021
    Applicants: Precigen, Inc., PGEN Therapeutics, Inc.
    Inventors: Douglas E. BROUGH, Cheryl G. BOLINGER, Ramya YARLAGADDA, Vinodhbabu KURELLA, Ponraj PRABAKARAN, Simon METENOU, Kuan-Fu DING
  • FUSION CONSTRUCTS AND METHODS OF USING THEREOF
    Publication number: 20200048351
    Abstract: Provided herein is a composition comprising a fusion protein or a fragment or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a TGF-? trap. Provided herein is a composition comprising a fusion protein or a fragment thereof or a variant thereof comprising an anti-PD1 antibody or a fragment/variant thereof and a ADA2 polypeptide. Also provided herein are methods of using the composition in treating cancer.
    Type: Application
    Filed: July 9, 2019
    Publication date: February 13, 2020
    Inventors: Helen Sabzevari, Simon Metenou, ChangHung Chen, Rutul R. Shah
  • MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20190031785
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 31, 2019
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU
  • MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20180318417
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 8, 2018
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU
  • COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-BETA
    Publication number: 20180251548
    Abstract: The present disclosure relates the combined effect of anti-CD155 [CD155, Nectin-like protein 5 (Nec1-5), Tage4, HVED, poliovirus receptor (PVR)] antibodies or anti TIGIT antibodies [TIGIT (T cell immunoreceptor with Ig and ITIM domains), WUCAM (Washington University cell adhesion molecule), Vstm3 (V-set and transmembrane domaincontaining protein 3), Vsig9 (V-set and immunoglobulin domain-containing protein 9)] with a TGF Beta 1 antagonist. The effect is measured by increased IFN-gamma production human breast adenocarcinoma cells. Use of combined antibodies /CD155 or TIGIT) with a TGF-Beta 1 antagon-ist to treat a patient with cancer is claimed.
    Type: Application
    Filed: September 14, 2016
    Publication date: September 6, 2018
    Inventors: Helen SABZEVARI, Simon METENOU